GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals
GLP-1 receptor agonists like semaglutide are often described as “game changers” for weight loss and cardiovascular health, and in many ways, the data support that claim. Clinical trials suggest meaningful reductions in major cardiovascular events, offering hope for individuals struggling with metabolic disease.
But there’s an important nuance that deserves more attention: what happens when these medications are stopped?
In this conversation, Dr. Bret Scher explores emerging real-world data showing that the benefits of GLP-1s, particularly for cardiovascular risk, appear to depend on continued…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.